(Alliance News) - Oxford Biomedica PLC announced on Wednesday it has signed a license and multi-year supply agreement with Philadelphia-based biotechnology company Cabaletta Bio Inc for its LentiVector platform.
The Oxford-based gene and cell therapy company said the financial arrangements of the license and supply agreement are "in line with comparable deals the group has previously secured".
The agreement grants Cabaletta Bio with a non-exclusive license to the company's LentiVector platform, which will be used by Cabaletta Bio in its chimeric autoantibody receptor T programme focused on DSG3-CAART.
DSG3-CAART is being developed to treat mucosal pemphigus vulgaris, a blistering skin disease that affects mucous membranes.
Oxford Biomedica's LentiVector platform is a lentiviral-based gene delivery system that enables the development of gene and cell-based medicines. Lentivirus is a type of virus that causes chronic and deadly illnesses such as AIDS.
Shares in Oxford Biomedica were up 0.5% at 1,216.00 pence each on Wednesday morning in London.
By Heather Rydings; heatherrydings@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Oxford Biomedica (OXB)